Opendata, web and dolomites

V-LAP SIGNED

A revolutionary direct, daily heart monitoring platform for long-term tailored treatment of Heart Disease patients.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 V-LAP project word cloud

Explore the words cloud of the V-LAP project. It provides you a very rough idea of what is the project "V-LAP" about.

lv    weeks    powered    filling    coupling    98    patients    disruptive    heart    ventricular    30    color    sudden    promptly    mortality    unable    medications    12    diabetes    invasively    completely    minimally    collected    inductive    ineffective    catheter    procedure    hemodynamic    lap    free    ac    red    hospitalization    earliest    causes    website    nhs    fluids    decreasing    global    sent    meet    detecting    quality    edema    miniaturized    decompensate    yellow    portfolio    invasive    least    data    provider    covered    worldwide    adjust    hf    green    worn    worsening    clinicians    daily    leg    hospital    back    predict    device    65    levels    life    adhf    threatening    symptoms    left    flow    swelling    people    28    prescription    transition    indicator    patient    patents    expenditure    chronic    healthcare    acute    pump    total    implantable    glucose    pressure    synchronize    battery    aged    dyspnea    code    takes    clothes    vectorious    blood    day    organs    tiredness    events       min    monitor    body    measured    ing    excess    belt    external    mobile   

Project "V-LAP" data sheet

The following table provides information about the project.

Coordinator
VECTORIOUS MEDICAL TECHNOLOGIES LTD 

Organization address
address: RAUL WALLENBERG 24
city: TEL AVIV JAFFA
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://vectoriousmedtech.com/
 Total cost 2˙621˙146 €
 EC max contribution 1˙834˙802 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VECTORIOUS MEDICAL TECHNOLOGIES LTD IL (TEL AVIV JAFFA) coordinator 1˙834˙802.00

Map

 Project objective

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed through a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes.

 Deliverables

List of deliverables.
Project webpage Websites, patent fillings, videos etc. 2019-07-22 17:27:08

Take a look to the deliverables list in detail:  detailed list of V-LAP deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Leor Perl, Elina Soifer, Jozef Bartunek, Dedi Erdheim, Friedrich Köhler, William T. Abraham, David Meerkin
A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience
published pages: , ISSN: 1937-5387, DOI: 10.1007/s12265-018-9856-3
Journal of Cardiovascular Translational Research ~13K Publications so far 2019-07-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V-LAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "V-LAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More